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Shimizu and colleagues1 have dem-
onstrated that both VPI and tumor size
had a significant impact on survival for
patients with NSCLC in univariate anal-
ysis. However, tumor size failed to be
a predictor of survival in multivariate
analysis, whereasVPI was still a signifi-
cant predictor for all patients with
NSCLC (P<.001) and those with stage
I disease (P¼ .0104).VPI overwhelmed
tumor size as a prognostic factor for
NSCLC in their study. However, most
studies in the literature have reported tu-
mor size as a significant prognostic fac-
tor in NSCLC. The International
Association for the Study of Lung Can-
cer Lung Cancer Staging Project Com-
mittee has recommended that T1
tumors be classified as T1a (2 cm)
and T1b (>2 to 3 cm) and that T2
tumors be classified as T2a (>3 to
5 cm), T2b (>5 to 7 cm), and T3
(>7 cm).5 However, revision of non–
size-based T2 descriptors has not been
recommended because of the small
number of patients, inconsistent clinical
and pathologic results, or lack of valida-
tion.5 Their proposal emphasized the
prognostic value of tumor size in
NSCLC. Shimizu and colleagues1
have also demonstrated that VPI was
significantly associated with tumor
size. We wonder how the authors dealt
with the interaction of the 2 variables
in multivariate analysis and interpreted
the greater effect of VPI on survival in
their study.
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Letters to the Editor
The JournSERUM BRAIN NATRIURETIC
PEPTIDE FOR PREDICTION OF
SUCCESSFUL MEDICAL
TREATMENT OF PATENT
DUCTUS ARTERIOSUS IN
PREMATURE INFANTS
To the Editor:
Wereadwith great interest the report
by Tschuppert and colleagues1 entitled
‘‘The Effect of Ductal Diameter on
Surgical andMedical Closure of Patent
Ductus Arteriosus in Preterm Neo-
nates: Size Matters’’ and the relevant
letter by Giardini and colleagues.2
Although Tschuppert and col-
leagues suggested that the size of
a patent ductus arteriosus (PDA) can
be used to predict patients in whom
medical management is likely to fail
to achieve hemodynamic irrelevance,
Giardini and colleagues claimed that
the difference in PDA diameter in pa-
tients who did and did not respond toal of Thoracic and Cardiovascular Surgmedical treatment was extremely low
and questioned how such a small dif-
ference can be clinically significant.2
We would like to add some com-
ment regarding factors other than
PDA size to predict successful medical
treatment according to our pilot study.
Recent reports suggesting that se-
rum brain natriuretic peptide (sBNP)
levels are parallel to the severity of
PDA3-5 prompted us to investigate
the relationship between the dose of
indomethacin and the levels of sBNP
or maximum diameter of PDA by
ultrasound cardiography (USCG)
during the first week of life. Indometh-
acin was repeatedly (1–4 times) ad-
ministered intravenously at a single
dose of 0.1 to 0.2 mg/kg until the clo-
sure of the PDA was confirmed by
USCG. sBNPwas measured by a com-
mercially available kit using fluores-
cent immunoassay (‘‘Shiono-Spot,’’
Shionogi Pharmaceutical Co, Osaka,
Japan). The required blood volume is
only 70 mL, and a result can be ob-
tained within 15 minutes with this kit.
There was a significant relationship
between the peak levels of sBNP
within 5 days of life and the total
dose of indomethacin (n ¼ 8, r ¼
0.78, P< .05, Table). Notably, the re-
quired total dose of indomethacin to
close a symptomatic PDA was 0.1 to
0.2 mg/kg in the infants with sBNP
levels less than 1000 pg/mL, whereas
the required dose was 0.3 mg/kg or
more in those with higher sBNP levels
(>2000 pg/mL), as shown in Table 1.TABLE 1. Relationship among serum levels of brain natriuretic peptide, size of patent ductus
arteriosus, and total dose of indomethacin
Case no.
Gestational
age (wk)
Total dose of
indomethacin (mg/kg)
Age at PDA
closure* (d)
Peak levelsy of
sBNP (pg/mL)
Maximum
diameter of
PDA (mm)
1 27.7 0.1 5 640.4 1.5
2 27.7 0.2 8 40.9 1.2
3 31.4 0.2 3 83.2 1.4
4 28.0 0.2 3 796.5 1.5
5 28.7 0.2 3 152.3 2.1
6 28.7 0.3 16 >2000 2.1
7 29.9 0.6 5 >2000 3.9
8z 29.9 0.7 14 >2000 3.3
PDA, Patent ductus arteriosus; sBNP, serum brain natriuretic peptide. *Confirmed by ultrasound echocardiography.
yMeasured within 5 days of life. zPDA reopened at the age of 16 days and received surgical ligation.ery c Volume 138, Number 1 261
MECHANISM OF
MYOCARDIAL PROTECTION
BY PRESSURE-VOLUME
UNLOADING INVOLVES
STRETCH-INDUCED
PATHOPHYSIOLOGY
To the Editor:
I read with interest the recent report
by Tamareille and colleagues,1 who
demonstrate in a porcine model of
myocardial infarction that left ventric-
ular (LV) unloading with a left ventric-
ular assist device (LVAD) during early
reperfusion is associated with both re-
duced endothelin-1 release by themyo-
cardium and reduced infarct size. They
demonstrate a positive correlation be-
tween early post-ischemia endothelin
release and infarct size but admit that
a cause–effect relationship was not es-
tablished by this study. They found no
effect of LV unloading on regional
myocardial blood flow. Our laboratory
previously demonstrated that LV un-
loading during early reperfusion ame-
liorates myocardial stunning in
a canine model of regional ischemia-
reperfusion.2 As did Tamareille and
colleagues, we found no differences
in regional myocardial blood flow be-
tween LVAD-treated and untreated an-
imals. By using ultrasonic dimension
crystals, however, we observed
marked ischemia-induced segmental
stretch during both systole (paradoxi-
cal bulging) and diastole (creep),
phenomena that were completely
eliminated by LV pressure-volume un-
loading. We hypothesized that LVAD-
mediated alleviation of abnormal
stretch was responsible for improved
contractile function. We later tested
this hypothesis in an isolated guinea
pig papillary muscle model,3 in which
we demonstrated that abnormal stretch
caused contractile dysfunction similar
to stunning. This dysfunction was
abolished by gadolinium, a lanthanide
cation that blocks a variety of stretch-
induced perturbations in cardiac func-
tion through mechanisms that may in-
volve specific stretch-activated ion
channels. We then returned to the ca-
nine model and demonstrated that ga-
dolinium attenuates regional stunning
to the extent of mechanical LV unload-
ing.4 I would therefore suggest to the
authors that the mechanism of infarct
reduction with LV unloading observed
in their studywas not reduced endothe-
lin release, but the elimination of ab-
normal stretch, which also happened
to reduce endothelin release.
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Letters to the EditorFurthermore, closure of the PDA oc-
curred within 10 days in all of 5 infants
demonstrating lower levels of sBNP
(<1000 pg/mL), whereas closure oc-
curred in only 1 of 3 infants with
higher levels (>2000 pg/mL): One in-
fant who required the largest dose of
indomethacin finally required opera-
tive ligation for the PDA because it re-
opened (case number 8 in Table 1).
From these findings, we suggest
that the hemodynamic severity of the
PDA in addition to the size of the
PDA should be taken into consider-
ation to predict the possibility of suc-
cessful medical treatment and to seek
the timing of surgical intervention be-
cause no single parameter can be
a complete index. The measurement
of sBNP in the early postnatal days
can be adjunctive and useful for these
purposes because it is rather objective
than the measurement of PDA diame-
ter by USCG and requires only a small
blood sample.
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